A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet
Enno FreyeCenter of Ambulatory Pain Medicine, Neuss-Uedesheim, GermanyAbstract: Breakthrough pain, a transitory severe pain with the background of otherwise controlled persistent pain has a prevalence between 52% and 67% in outpatients with cancer. Medications for such sudden-onset pain require non-...
Main Author: | Enno Freye |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2008-12-01
|
Series: | Journal of Pain Research |
Online Access: | http://www.dovepress.com/a-new-transmucosal-drug-delivery-system-for-patients-with-breakthrough-a2725 |
Similar Items
-
Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain
by: Prommer E, et al.
Published: (2012-06-01) -
The application of oral transmucosal fentanyl for the treatment of breakthrough pain in cancer patients
by: D V Nevzorova, et al.
Published: (2017-06-01) -
Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
by: Darbà J, et al.
Published: (2013-12-01) -
Buccal transmucosal delivery of large molecule therapeutics using orally disintegrating tablet technology
by: Iyire, Affiong
Published: (2016) -
Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study
by: Arturo Cuomo, et al.
Published: (2020-04-01)